Fig. 3.

HM71224 inhibits enlargement of the spleen and lymph nodes resulting from disease development. a In MRL/lpr mice, the organ weights of the spleen and cervical lymph nodes (LN) were significantly reduced by treatment with 10 and 30 mg/kg of HM71224 for 20 weeks (n = 11 per vehicle-treated group, n = 12 per HM71224-treated group). b In NZB/W F1 mice, spleen weight was significantly reduced by HM71224 treatment, whereas the weight of cervical lymph nodes showed a nonsignificant trend toward decrease after treatment for 24 weeks (n = 8 per vehicle-treated group, n = 9 per 3 mg/kg of HM71224-treated group, n = 12 per 10 and 30 mg/kg of HM71224-treated group). Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 versus vehicle control, analyzed by the Kruskal–Wallis test